By Digifin Pty Ltd · About this coverage
Key Points
- Revenue of US$1,415 million, up 6% and up 7% on a core constant currency basis
- Non-GAAP gross margin up 50 basis points to 62.5%
- Non-GAAP diluted EPS up 14% to US$2.91
- FY 2027 guidance unchanged at reported revenue of US$5.75 - US$5.85 Billion
- Quarterly cash dividend of US$0.66 per share declared
About Resmed (ASX:RMD)
Resmed Inc. is a medical device and health software company headquartered in San Diego, California. It designs and sells continuous positive airway pressure devices, ventilators, masks and related accessories used to treat sleep apnoea, chronic obstructive pulmonary disease and other respiratory conditions, alongside cloud-connected software for patients and out-of-hospital care providers. Its common stock is listed on the New York Stock Exchange and CHESS Depositary Interests are quoted on the ASX under the code RMD.
Resmed (ASX:RMD) reported first quarter fiscal year 2027 results showing revenue and earnings growth in a quarter in which it closed the MatrixCare divestiture and returned more than US$1.0 billion to shareholders through share repurchases and dividends.
All figures are unaudited and in US dollars. Revenue was US$1,415 million, up 6%, and up 7% on a core constant currency basis, which excludes the Noctrix acquisition and the MatrixCare divestiture. On that basis, Americas Sleep and Breathing Health revenue grew 7%, Rest of World Sleep and Breathing Health 8% and Residential Care Software 5%. Non-GAAP gross margin rose 50 basis points to 62.5%, against GAAP gross margin of 61.5%. GAAP operating margin was 32.0% and non-GAAP operating margin 35.8%. GAAP diluted earnings per share rose 23% to US$2.92 and non-GAAP diluted EPS rose 14% to US$2.91. Operating cash flow was US$422 million and free cash flow US$374 million, against US$457 million and US$414 million a year earlier. FY 2027 guidance is unchanged at core constant currency revenue growth of 5 - 7%, reported revenue of US$5.75 - US$5.85 Billion and non-GAAP diluted EPS of US$12.00 - US$12.25. The board declared a quarterly cash dividend of US$0.66 per share, payable on December 17, 2026.
Non-GAAP measures are calculated by the company. GAAP operating margin narrowed 140 basis points, cash flow was lower than a year earlier, and guidance was held rather than raised.
Source: Resmed Inc. (ASX:RMD), 30 October 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.